Literature DB >> 6158571

Alternative pathway complement activation in rheumatoid arthritis.

A El-Ghobarey, K Whaley.   

Abstract

Serum and synovial fluid (SF) levels of the complement components C3, C5, factor B (B), properdin (P), beta 1H and C3b inactivator (C3bINA), and EDTA-plasma and SF concentrations of C3d and Ba were measured in 40 rheumatoid arthritis (RA) and 5 patients with osteoarthritis. Decreased SF concentration of B and P and increased levels of Ba showed that increased alternative pathway turnover occurred in RA. Reduced SF C3bINA concentrations occurred, but levels of beta 1H were not reduced. The results showed that alternative pathway turnover was dependent upon C3 turnover, but failed to support the notion that levels of C3bINA or beta 1H control alternative pathway turnover in RA.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6158571

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

1.  Prevention of immune precipitation by purified classical pathway complement components.

Authors:  J K Naama; A O Hamilton; A C Yeung-Laiwah; K Whaley
Journal:  Clin Exp Immunol       Date:  1984-11       Impact factor: 4.330

2.  Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase.

Authors:  P J Jose; I K Moss; R N Maini; T J Williams
Journal:  Ann Rheum Dis       Date:  1990-10       Impact factor: 19.103

Review 3.  Complement and autoimmunity.

Authors:  Eleonora Ballanti; Carlo Perricone; Elisabetta Greco; Marta Ballanti; Gioia Di Muzio; Maria Sole Chimenti; Roberto Perricone
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

4.  The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease.

Authors:  B E Bourke; I K Moss; P Mumford; A Horsfall; R N Maini
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

5.  Relation between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis, and crystal associated arthropathy.

Authors:  M Doherty; N Richards; J Hornby; R Powell
Journal:  Ann Rheum Dis       Date:  1988-03       Impact factor: 19.103

6.  A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis.

Authors:  Eric Boilard; Ying Lai; Katherine Larabee; Barbara Balestrieri; Farideh Ghomashchi; Daisuke Fujioka; Reuben Gobezie; Jonathan S Coblyn; Michael E Weinblatt; Elena M Massarotti; Thomas S Thornhill; Maziar Divangahi; Heinz Remold; Gérard Lambeau; Michael H Gelb; Jonathan P Arm; David M Lee
Journal:  EMBO Mol Med       Date:  2010-05       Impact factor: 12.137

7.  A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples.

Authors:  Diana Pauly; Benedikt M Nagel; Jörg Reinders; Tobias Killian; Matthias Wulf; Susanne Ackermann; Boris Ehrenstein; Peter F Zipfel; Christine Skerka; Bernhard H F Weber
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

8.  Prognostic Value of Complement Properdin in Cancer.

Authors:  Alessandro Mangogna; Praveen M Varghese; Chiara Agostinis; Salman H Alrokayan; Haseeb A Khan; Cordula M Stover; Beatrice Belmonte; Anna Martorana; Giuseppe Ricci; Roberta Bulla; Uday Kishore
Journal:  Front Immunol       Date:  2021-01-19       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.